DekaBank Deutsche Girozentrale’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-17,000
| Closed | -$2.93M | – | 1553 |
|
|
2023
Q3 | $2.93M | Hold |
17,000
| – | – | 0.01% | 656 |
|
|
2023
Q2 | $1.7M | Hold |
17,000
| – | – | ﹤0.01% | 788 |
|
|
2023
Q1 | $1.5M | Sell |
17,000
-5,640
| -25% | -$331K | ﹤0.01% | 784 |
|
|
2022
Q4 | $826K | Hold |
22,640
| – | – | ﹤0.01% | 927 |
|
|
2022
Q3 | $559K | Hold |
22,640
| – | – | ﹤0.01% | 1020 |
|
|
2022
Q2 | $710K | Buy |
22,640
+6,000
| +36% | +$179K | ﹤0.01% | 955 |
|
|
2022
Q1 | $514K | Buy |
16,640
+1,500
| +10% | +$44.5K | ﹤0.01% | 1055 |
|
|
2021
Q4 | $357K | Buy |
15,140
+400
| +3% | +$31K | ﹤0.01% | 1169 |
|
|
2021
Q3 | $1.53M | Hold |
14,740
| – | – | ﹤0.01% | 790 |
|
|
2021
Q2 | $2.13M | Hold |
14,740
| – | – | 0.01% | 707 |
|
|
2021
Q1 | $1.4M | Hold |
14,740
| – | – | ﹤0.01% | 796 |
|
|
2020
Q4 | $1.89M | Sell |
14,740
-45,650
| -76% | -$6M | 0.01% | 681 |
|
|
2020
Q3 | $5.56M | Buy |
60,390
+53,390
| +763% | +$6.67M | 0.02% | 383 |
|
|
2020
Q2 | $1.06M | Sell |
7,000
-1,800
| -20% | -$274K | 0.01% | 642 |
|
|
2020
Q1 | $1.28M | Buy |
8,800
+1,300
| +17% | +$251K | 0.01% | 536 |
|
|
2019
Q4 | $1.58M | Buy |
+7,500
| New | +$1.37M | 0.01% | 583 |
|
|
2019
Q3 | – | Sell |
-45,300
| Closed | -$4.15M | – | 1151 |
|
|
2019
Q2 | $4.15M | Buy |
45,300
+37,900
| +512% | +$3.27M | 0.02% | 459 |
|
|
2019
Q1 | $639K | Sell |
7,400
-15,250
| -67% | -$1.27M | ﹤0.01% | 858 |
|
|
2018
Q4 | $1.18M | Buy |
22,650
+15,250
| +206% | +$931K | 0.01% | 642 |
|
|
2018
Q3 | $639K | Sell |
7,400
-200
| -3% | -$14.1K | ﹤0.01% | 879 |
|
|
2018
Q2 | $267K | Hold |
7,600
| – | – | ﹤0.01% | 1007 |
|
|
2018
Q1 | $152K | Buy |
+7,600
| New | +$196K | ﹤0.01% | 1019 |
|
DekaBank Deutsche Girozentrale's RETA Position: Q4 2023 in Review
DekaBank Deutsche Girozentrale sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2023, closing a stake of 17,000 shares — an estimated $2.93M sold.
DekaBank Deutsche Girozentrale first reported a position in RETA in Q1 2018 and held it in 22 quarters. The position peaked at $5.56M in Q3 2020. 0 funds tracked by Wall St. Rank hold RETA as of Q4 2023.
- DekaBank Deutsche Girozentrale reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2023 after selling out during the quarter.
- DekaBank Deutsche Girozentrale sold 17,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2023, an estimated $2.93M.
- DekaBank Deutsche Girozentrale first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2018 and held it in 22 quarters.
- DekaBank Deutsche Girozentrale's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $5.56M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2023.
Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2023, filed 24 Jan 2024.